Nasdaq: $25.89 (-0.35) | AIM: £3.75 (+0.05)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Apr 2014

AACR 2014: Targeting MET in preclinical models to support the clinical development of AZD6094/HMPL-504 (savolitinib) in NSCLC